[go: up one dir, main page]

SG10201701057SA - Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione - Google Patents

Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Info

Publication number
SG10201701057SA
SG10201701057SA SG10201701057SA SG10201701057SA SG10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA SG 10201701057S A SG10201701057S A SG 10201701057SA
Authority
SG
Singapore
Prior art keywords
oxoisoindolin
morpholinomethyl
dione
piperidine
oxy
Prior art date
Application number
SG10201701057SA
Other languages
English (en)
Inventor
Peter H Schafer
Anita Gandhi
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG10201701057SA publication Critical patent/SG10201701057SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
SG10201701057SA 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione SG10201701057SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681447P 2012-08-09 2012-08-09
US201261722727P 2012-11-05 2012-11-05

Publications (1)

Publication Number Publication Date
SG10201701057SA true SG10201701057SA (en) 2017-03-30

Family

ID=49004013

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201701057SA SG10201701057SA (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
SG10202108516PA SG10202108516PA (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
SG11201500998QA SG11201500998QA (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10202108516PA SG10202108516PA (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
SG11201500998QA SG11201500998QA (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Country Status (32)

Country Link
US (3) US20140045843A1 (he)
EP (2) EP2882442B1 (he)
JP (2) JP6347782B2 (he)
KR (3) KR102414005B1 (he)
CN (4) CN114366746A (he)
AU (1) AU2013299627C1 (he)
BR (1) BR112015002285B1 (he)
CA (1) CA2881116C (he)
CY (1) CY1124622T1 (he)
DK (1) DK2882442T3 (he)
EA (1) EA029485B1 (he)
ES (1) ES2881220T3 (he)
HK (1) HK1211489A1 (he)
HR (1) HRP20211243T1 (he)
HU (1) HUE056127T2 (he)
IL (3) IL288506B2 (he)
IN (1) IN2015DN00886A (he)
LT (1) LT2882442T (he)
MX (1) MX367869B (he)
NI (1) NI201500012A (he)
NZ (1) NZ628078A (he)
PH (1) PH12015500212A1 (he)
PL (1) PL2882442T3 (he)
PT (1) PT2882442T (he)
RS (1) RS62201B1 (he)
SG (3) SG10201701057SA (he)
SI (1) SI2882442T1 (he)
SM (1) SMT202100457T1 (he)
TW (2) TWI653977B (he)
UA (1) UA116544C2 (he)
WO (1) WO2014025960A1 (he)
ZA (1) ZA201500564B (he)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP3202461B1 (en) 2010-02-11 2018-12-26 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
CA2877736C (en) 2012-06-29 2021-12-07 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
MX2015003114A (es) 2012-09-10 2015-07-06 Celgene Corp Metodos para el tratamiento de cancer de mama localmente avanzado.
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
KR102299801B1 (ko) 2013-12-06 2021-09-10 셀진 코포레이션 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US20180267043A1 (en) * 2014-10-07 2018-09-20 Celgene Corporation Use of biomarkers for predicting clinical sensitivity to cancer treatment
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
US20180238886A1 (en) * 2017-01-31 2018-08-23 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
CN110996959A (zh) 2017-05-23 2020-04-10 梅制药公司 联合疗法
FI3644999T3 (fi) * 2017-06-30 2023-03-19 Celgene Corp 2-(4-kloorifenyyli)-n-((2-(2,6-dioksopiperidin-3-yyli)-1-oksoisoindolin-5-yyli)metyyli)-2,2-difluoriasetamidin koostumukset ja menetelmät sen käyttämiseksi
FI3651766T3 (fi) * 2017-07-10 2024-11-18 Celgene Corp 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
WO2019060693A1 (en) * 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
SG11202002753QA (en) 2017-10-26 2020-05-28 Nat Univ Singapore A new approach for universal monitoring of minimal residual disease in acute myeloid leukemia
IL315310A (he) 2017-12-26 2024-10-01 Kymera Therapeutics Inc מפרקי irak ושמושים בהם
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
EP3836936A4 (en) * 2018-08-14 2022-05-18 MEI Pharma, Inc. TREATMENT OF RECURRING FOLLICULAR LYMPHOMA
US11319330B2 (en) 2018-09-07 2022-05-03 Medshine Discovery Inc. Tricyclic furan-substituted piperidinedione compound
IL281845B2 (he) * 2018-10-01 2025-06-01 Celgene Corp טיפול משולב הכולל 3-(4-((4-(מורפולינומתיל)בנזיל)אוקסי)-1-אוקסואיזואנדולין-2-איל)פיפרידין-2,6-דיון ודראטומומב לטיפול במיאלומה נפוצה
US12263190B2 (en) * 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
BR112022007548A2 (pt) 2019-11-07 2022-07-12 Juno Therapeutics Inc Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
EP4069245A1 (en) 2019-12-02 2022-10-12 Celgene Corporation Therapy for the treatment of cancer
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
IL296451A (he) 2020-03-19 2022-11-01 Kymera Therapeutics Inc מפרקי mdm2 ושימושים בהם
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4171550A1 (en) * 2020-06-25 2023-05-03 Celgene Corporation Methods for treating cancer with combination therapies
KR20230143632A (ko) 2020-12-30 2023-10-12 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
IL312397A (he) 2021-10-29 2024-06-01 Kymera Therapeutics Inc מפרקי irak4 וסינתיזה שלהם
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2024015618A2 (en) * 2022-07-15 2024-01-18 St. Jude Children's Research Hospital, Inc. Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025120113A1 (en) 2023-12-08 2025-06-12 Celgene Corporation Therapy for the treatment of multiple myeloma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CA2587424A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
AU2008229383B2 (en) * 2007-03-20 2013-09-05 Celgene Corporation 4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
EP3202461B1 (en) * 2010-02-11 2018-12-26 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
TWI509247B (zh) * 2010-03-12 2015-11-21 Celgene Corp 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
US20140148473A1 (en) * 2011-03-11 2014-05-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases

Also Published As

Publication number Publication date
EA029485B1 (ru) 2018-04-30
KR102266510B1 (ko) 2021-06-16
PL2882442T3 (pl) 2021-12-13
AU2013299627C1 (en) 2018-05-31
DK2882442T3 (da) 2021-08-16
BR112015002285A2 (pt) 2017-07-04
NZ628078A (en) 2017-01-27
TW201434466A (zh) 2014-09-16
KR20150039850A (ko) 2015-04-13
TWI653977B (zh) 2019-03-21
KR20210073617A (ko) 2021-06-18
CN114366746A (zh) 2022-04-19
JP2015524478A (ja) 2015-08-24
US20140045843A1 (en) 2014-02-13
MX2015001775A (es) 2015-05-12
IL288506A (he) 2022-01-01
KR102414005B1 (ko) 2022-06-27
TWI723266B (zh) 2021-04-01
MX367869B (es) 2019-09-10
CN108245518B (zh) 2021-08-31
BR112015002285B1 (pt) 2022-05-10
UA116544C2 (uk) 2018-04-10
PT2882442T (pt) 2021-08-17
US20160256468A1 (en) 2016-09-08
EP2882442B1 (en) 2021-06-09
IL276319B (he) 2022-01-01
LT2882442T (lt) 2021-09-27
CN114344307A (zh) 2022-04-15
CY1124622T1 (el) 2022-07-22
NI201500012A (es) 2019-05-10
SG11201500998QA (en) 2015-04-29
JP6347782B2 (ja) 2018-06-27
IN2015DN00886A (he) 2015-06-12
CA2881116C (en) 2021-07-20
IL288506B1 (he) 2023-05-01
ZA201500564B (en) 2016-06-29
JP2018100276A (ja) 2018-06-28
IL288506B2 (he) 2023-09-01
EP2882442A1 (en) 2015-06-17
RS62201B1 (sr) 2021-08-31
HUE056127T2 (hu) 2022-01-28
KR102146848B1 (ko) 2020-08-21
HRP20211243T1 (hr) 2021-11-12
WO2014025960A1 (en) 2014-02-13
IL237013A0 (he) 2015-03-31
ES2881220T3 (es) 2021-11-29
AU2013299627B2 (en) 2018-02-15
HK1211489A1 (en) 2016-05-27
EA201590345A1 (ru) 2015-06-30
SG10202108516PA (en) 2021-09-29
EP3949968A1 (en) 2022-02-09
KR20200098730A (ko) 2020-08-20
PH12015500212A1 (en) 2015-03-30
SI2882442T1 (sl) 2021-11-30
CN108245518A (zh) 2018-07-06
US20190388429A1 (en) 2019-12-26
TW201828944A (zh) 2018-08-16
CA2881116A1 (en) 2014-02-13
CN104837491A (zh) 2015-08-12
SMT202100457T1 (it) 2021-09-14
IL237013B (he) 2020-08-31
AU2013299627A1 (en) 2015-02-05
IL276319A (he) 2020-09-30

Similar Documents

Publication Publication Date Title
IL288506A (he) שיטות לטיפול בסרטן באמצעות 3–(4–((4–(מורפולינומתיל)בנזיל) אוקסי)–1–אוקסואיזואנדולין–2–יל) פיפרידין–2,6–דיון
ZA201306305B (en) Methods of treating cancer using 3-(5-amino-2-methyl-4h-quinazolin-3-yl)-piperidine-2,6-dione
IL244494A0 (he) פורמולציות של 3-(4-((4-(מורפולינומתיל)בנזיל) אוקסי)-1-אוקסואיזואינדולין-2-איל)פיפרידין-6,2-דיאון
IL236922A0 (he) מלחים וצורות מוצקות של (4))–4)–3–(s–מורפולינומתיל)בנזיל)אוקסי)–1–אוקסואיזואינדולין–2–איל)פיפרידין–6,2–דיאון והרכבים המכילים אותם ושיטות לשימוש שלהם
IL236925A0 (he) תהליכים להכנת (s)–3–4–((4–מורפולינומתיל)בנזיל)אוקסי)–1–אוקסואיזואינדולין–2–איל)פיפרידין–6,2–דיאון וצורות רוקחיות מקובלות שלהם